Lowering the entry barrier, Novo Nordisk considers flexible pricing for "miracle weight-loss drug".

"Wegovy," the "miracle weight-loss drug," has become extremely popular worldwide, and Novo Nordisk has quickly become the most valuable listed company in Europe in the "battle of weight-loss drugs." In light of this, Novo Nordisk is considering adopting flexible pricing for this "miracle weight-loss drug." On November 27th, Lars Fruergaard Jrgensen, the CEO of the Danish pharmaceutical giant Novo Nordisk, stated in an interview with the media that the company is willing to maintain "flexibility" in its pricing strategy. They are currently negotiating an innovative pricing agreement with healthcare payers for Wegovy, allowing medical service providers to pay in installments and reduce the pressure of one-time payments, thus expanding the usage of Wegovy. Jrgensen pointed out that in order to make substantial progress in treating obesity and other diseases, the number of patients who need treatment should far exceed the current millions of patients using the drug. In light of this, Novo Nordisk is willing to share the costs and is open to any type of arrangement that will be reached with the healthcare payers.